Ultragenyx and Mereo BioPharma: What Analysts Are Saying After Trial Setbacks
Analysts react to disappointing ORBIT and COSMIC trial results for Ultragenyx and Mereo BioPharma, highlighting risks, ratings changes, and what could come next.
/ 3 items
#RARE↓
Ultragenyx's Bone Disease Drug Fails Key Clinical Trials
Ultragenyx's setrusumab fails to reduce fractures in osteogenesis imperfecta patients in Phase 3 trials, though bone density improved. Company plans expense cuts.
Why Ultragenyx Stock Might Be Ready to Climb
JPMorgan is optimistic about Ultragenyx's drug setrusumab (UX143) and expects big gains ahead of key study updates.